Recently, published data have clearly indicated that immunotherapy (anti-CTLA-4 and anti-PD-1/PD-L1 antibodies) represents an important therapeutic option for HNSCC patients. The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.